Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Google Secures Pentagon AI Deal for Classified Projects 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
CHICAGO, Feb. 10, 2016 -- AveXis, Inc. (Nasdaq:AVXS), a clinical stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced the pricing of its initial public offering of 4,750,000 shares of common stock at an initial public offering price of $20.00 per share, before underwriting discounts. In addition, AveXis has granted the underwriters a 30-day option to purchase up to an additional 712,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions. All of the shares are being offered by AveXis. The shares are expected to begin trading on The NASDAQ Global Select Market on February 11, 2016 under the ticker symbol "AVXS." The offering is expected to close on February 17, 2016, subject to customary closing conditions.
AveXis intends to use its existing cash and cash equivalents and the net proceeds of the offering, expected to total $85.9 million, to fund the ongoing Phase 1 clinical trial and future spinal muscular atrophy trials of AVXS-101; for manufacturing activities to support ongoing and future trials for AVXS-101, including the establishment of the Company’s own manufacturing facility; and for general corporate purposes and working capital.
Goldman, Sachs & Co. and Jefferies LLC are acting as joint book-running managers. BMO Capital Markets Corp. is acting as lead manager and Chardan is acting as co-manager of the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on February 10, 2016. The offering will be made only by means of a prospectus, copies of which may be obtained for free from the offices of Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, NY 10282; by telephone at 1-866-471-2526; or by email at [email protected] or Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022; by phone at 1-877-547-6340; or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
About AveXis, Inc.
AveXis is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company’s initial proprietary gene therapy candidate, AVXS-101, is in an ongoing Phase 1 clinical trial for the treatment of SMA Type 1.
Media Inquiries: Lauren Barbiero W2O Group 646-564-2156 [email protected]
